Nancy M. Schlichting - 03 Dec 2021 Form 4 Insider Report for Pear Therapeutics, Inc.

Role
Director
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Dec 2021
Net transactions value
$0
Form type
4
Filing time
07 Dec 2021, 16:26:03 UTC
Previous filing
23 Nov 2021
Next filing
14 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Award +110,430 110,430 03 Dec 2021 Common Stock 110,430 $1.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 33% of the shares underlying the option vested or shall vest on December 1, 2021, an additional 33% of the shares vested or shall vest on December 1, 2022, and an additional 34% of the shares vested or shall vest on December 1, 2023.
F2 Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 75,000 shares of common stock of Private Pear for $1.77 per share.